Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications
27 juin 2024 09h43 HE
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
07 juin 2024 20h18 HE
|
Qu Biologics, Inc.
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial...
![Immune Network Ltd Logo](/news-release/logo/214799/0/214799.jpg?lastModified=12%2F09%2F2016%2023%3A15%3A24&size=2)
Herbal TB Immunotherapy to be Presented at Hong Kong Conference
07 juil. 2011 10h33 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, July 7, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF) advises that clinical results from its new tableted form of Immunoxel (Dzherelo) product...
![Immune Network Ltd Logo](/news-release/logo/214799/0/214799.jpg?lastModified=12%2F09%2F2016%2023%3A15%3A24&size=2)
Immunitor Publishes Interim Data From Phase IIb imm01 TB Trial
30 déc. 2010 04h41 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, Dec. 30, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that Immunitor has published data from the first half of the 120-patient imm01 clinical...
![Immune Network Ltd Logo](/news-release/logo/214799/0/214799.jpg?lastModified=12%2F09%2F2016%2023%3A15%3A24&size=2)
Immunitor Phase 2b imm01 Trial Enrollment Scheduled to Complete Next Week
01 nov. 2010 09h42 HE
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), a company in the business of discovery and development of immune-based therapies, today announced...